2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
138
Neoplasms
118
Prostatic Neoplasms
64
Lung Neoplasms
48
Head and Neck Neoplasms
46
Colorectal Neoplasms
38
Ovarian Neoplasms
33
Uterine Cervical Neoplasms
29
Endometrial Neoplasms
23
Motor Activity
22
Neoplasm Metastasis
20
Multiple Myeloma
20
Pancreatic Neoplasms
19
Brain Neoplasms
19
Rectal Neoplasms
18
Lymphoma
17
Colonic Neoplasms
17
Pain
16
Gastrointestinal Neoplasms
16
Fatigue
16
Carcinoma, Non-Small-Cell Lung
16
Leukemia
15
Depression
15
Oropharyngeal Neoplasms
13
Melanoma
13
Anxiety Disorders
13
Urinary Bladder Neoplasms
12
Hematologic Neoplasms
12
Esophageal Neoplasms
12
Stomach Neoplasms
11
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Surveys and Questionnaires
×
Clear all
NCT01126346
2018-07-03
HOPE
Wake Forest University Health Sciences
Phase NA
Completed
10 enrolled